Ivermectin and Benzoyl Peroxide Lead Rosacea Treatment
Topical ivermectin and encapsulated benzoyl peroxide appear to be the most effective FDA-approved topical treatments for papules and pustules of rosacea when compared with standard first-line therapy. A network meta-analysis published in JAMA Dermatology confirms both treatments were associated with greater reductions in inflammatory lesion counts and higher rates of achieving clear or almost clear skin compared with metronidazole and other options. However, the data reveals a sharp divide in patient tolerability: encapsulated benzoyl peroxide was associated with greater rates of discontinuation due to adverse effects.
Comparing Lesion Reduction and Clinical Success
The meta-analysis, which examined 32 randomized controlled trials involving 11,399 participants, paints a clear picture of clinical efficacy. Ivermectin demonstrated a mean difference of 4.17 lesions compared to metronidazole, while encapsulated benzoyl peroxide followed closely with a mean difference of 4.14 lesions.
Success is also measured by the Investigator Global Assessment (IGA). In this category, both treatments were associated with a greater likelihood of achieving IGA success when compared with metronidazole. Encapsulated benzoyl peroxide achieved a 15.51 percentage point increase in success rates, while ivermectin recorded a 10.31 percentage point increase over metronidazole.
The Trade-off: Irritation Versus Potency
Despite its potency, encapsulated benzoyl peroxide poses a distinct challenge for patients. Clinical data shows a mean difference of 8.33 for discontinuation due to tolerability concerns compared to first-line treatment. Patients frequently cited pain, erythema, pruritus, and edema as primary drivers for stopping the regimen.
John Barbieri, MD, MBA, an associate professor at Harvard Medical School and a Healio Dermatology Peer Perspective Board Member, acknowledges the clinical value of the drug but warns of its limitations. “These findings suggest that encapsulated benzoyl peroxide can be a highly effective option, particularly for those who may have had an inadequate response to other treatments,” Barbieri said. He notes it may not be the best option for those with extremely sensitive skin and recommends combining it with good skin care, including sun protection and moisturizer use, to maximize tolerability.
Strategic Choices for Maintenance
Given the side-effect profile, topical ivermectin may be a more suitable choice for long-term maintenance therapy. Yet, the medical community lacks robust data on the long-term outcomes of these interventions. Current research gaps include a lack of head-to-head trials, a shortage of data on the durability of response and how best to approach maintenance therapy, and insufficient evidence regarding how treatments for redness compare with each other. Furthermore, few trials included patient-reported outcomes, which is a gap with respect to capturing patient-centered outcomes.
Navigating Treatment Decisions
As Dr. Barbieri notes, clinicians must continue to weigh the potential for drug-related irritation against the severity of the patient's condition to determine the most appropriate long-term treatment plan.